ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs’ Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, ...

Core Points - A class action has been filed against Compass Group Diversified Holdings, LLC (NYSE: CODI) on behalf of investors who acquired its securities between May 1, 2024, and May 7, 2025 [1] - The allegations include insufficient disclosure controls and failure to disclose unrecorded financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable related to its subsidiary, Lugano Holdings, Inc. [2] - On May 7, 2025, Compass announced the need to restate its financial statements for fiscal 2024 due to identified irregularities in Lugano's financing and accounting practices, leading to a significant drop in stock price [3] Company Information - Compass Group Diversified Holdings, LLC is a statutory trust that manages a portfolio of small and middle-market businesses, including Lugano Holdings, Inc., which specializes in high-end jewelry [1] - The company is currently under investigation for its financial disclosures and practices related to its subsidiary [2][3] Legal Proceedings - Shareholders interested in participating in the class action must file their papers by July 8, 2025, to serve as lead plaintiff [4] - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur fees or expenses [5]

SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Solaris Energy Infrastructure, Inc. (NYSE: SEI) securities between July 9, 2024 and March 17, 2025. Solaris provides equipment used in the completion of oil and natural gas wells in the United States. On July 9, 2024, Solaris announced that it has entered into an agreement to acquire Mobile Energy Rentals LLC (“MER”). For more i ...

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP, a distinguished law firm with over 125 years of history, informs investors that a class action lawsuit has been filed against Civitas Resources, Inc. ("Civitas " or the "Company") (NYSE: CIVI) on behalf of a class consisting of all investors that purchased or otherwise acquired Civitas securities between February 27, 2024 and February 24, 2025, both dates inclusive (the "Class Period"). Deadline to sign up: If you are an i ...

SAN DIEGO, May 7, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025. West is a medical supplies company that specializes in the development, manufacture, and distribution of elastomer-based supplies for the containment and administration of injectable drugs.For more information, submit a form, ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Avis To Contact Him Directly To Discuss Their Options NEW YORK, May 7, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Avis Budget Group, Inc. ("Avis" or the "Company") (NASDAQ: CAR) and reminds investors of the June 24, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been ...

Core Insights - A class action lawsuit has been filed against Civitas Resources, Inc. for allegedly misleading investors regarding its production capabilities and financial condition [1][2] Group 1: Allegations and Impact - The lawsuit claims that Civitas failed to disclose a likely significant reduction in oil production for 2025 due to declines following a production peak in the DJ Basin in Q4 2024 and a low TIL count at the end of 2024 [2] - It is alleged that increasing oil production would necessitate acquiring additional acreage and development locations, leading to significant debt and potential asset sales [2] - The company's financial condition reportedly required disruptive cost-reduction measures, including a significant workforce reduction, which overstated its business and financial prospects [2] - Following the revelation of these issues on February 24, 2025, Civitas's stock price dropped by $8.95 per share, over 18%, closing at $40.35 on February 25, 2025 [2] Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers with the court by July 1, 2025 [3] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3] Group 3: Company Background - Civitas Resources, Inc. is an independent exploration and production company focused on crude oil and liquids-rich natural gas in the DJ Basin and the Permian Basin [1]

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Humana Inc. (“Humana” or the “Company”) (NYSE:HUM). The investigation concerns whether Humana and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On May 1, 2025, the U.S. Department of Justice filed a complaint against insurance broker organizations, including Humana, alleging t ...

Core Viewpoint - PTC Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following the announcement of Phase 2 study results for its treatment of Huntington's disease, which led to a significant drop in stock price [1][2][3]. Group 1: Company Developments - PTC announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease patients, achieving its primary endpoint of reducing blood Huntingtin protein levels with a p-value of less than 0.0001 at Week 12 [2]. - Despite meeting the primary endpoint, analysts suggest that a Phase 3 study may be necessary to confirm the treatment's efficacy in slowing the progression of Huntington's disease [2]. Group 2: Market Reaction - Following the announcement of the study results, PTC's stock price fell by $9.30 per share, representing an 18.62% decline, closing at $40.65 per share on May 5, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Arvinas, Inc. and its officers or directors [1] Group 1: Company Developments - On May 1, 2025, Arvinas announced the removal of plans for a Phase 3 first-line combination trial with atirmociclib and a second-line combination trial with a CDK4/6 inhibitor from its joint development plan with Pfizer [2] - The decision to remove these trials was based on a review of emerging information, external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation [2] - Arvinas also announced a workforce reduction of approximately one-third to streamline operations and enable efficient progression of its portfolio, with completion planned for the second quarter of 2025 [2] - Following this news, Arvinas's stock price fell by $2.39 per share, or 24.84%, closing at $7.23 per share on May 1, 2025 [2]